Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Sun Pharmaceutical Industries Ltd is up for a third straight session today. The stock is quoting at Rs 1638.8, up 1.15% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.19% on the day, quoting at 25378.1. The Sensex is at 82867.93, up 0.21%. Sun Pharmaceutical Industries Ltd has gained around 0.75% in last one month.
Meanwhile, Nifty Pharma index of which Sun Pharmaceutical Industries Ltd is a constituent, has gained around 1.43% in last one month and is currently quoting at 22241.35, up 0.63% on the day. The volume in the stock stood at 11.32 lakh shares today, compared to the daily average of 26.7 lakh shares in last one month.
The benchmark September futures contract for the stock is quoting at Rs 1643.3, up 1.08% on the day. Sun Pharmaceutical Industries Ltd is down 11.23% in last one year as compared to a 0.15% slide in NIFTY and a 2.39% slide in the Nifty Pharma index.
The PE of the stock is 78.05 based on TTM earnings ending June 25.
Sun Pharmaceutical Industries Ltd is up for a third straight session today. The stock is quoting at Rs 1612.3, up 1.19% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.1% on the day, quoting at 24997.1. The Sensex is at 81530.73, up 0.13%. Sun Pharmaceutical Industries Ltd has slipped around 0.61% in last one month.
Meanwhile, Nifty Pharma index of which Sun Pharmaceutical Industries Ltd is a constituent, has slipped around 2.11% in last one month and is currently quoting at 22122.05, up 0.41% on the day. The volume in the stock stood at 8.99 lakh shares today, compared to the daily average of 27.31 lakh shares in last one month.
The benchmark September futures contract for the stock is quoting at Rs 1616.7, up 1.09% on the day. Sun Pharmaceutical Industries Ltd is down 13.57% in last one year as compared to a 1.54% slide in NIFTY and a 5.19% slide in the Nifty Pharma index.
The PE of the stock is 76.77 based on TTM earnings ending June 25.
The classification follows an inspection conducted by the FDA from June 2 to June 13, 2025, during which eight observations related to current good manufacturing practices (CGMP) were issued.
Sun Pharma stated that the Halol site remains under an import alert, restricting shipments to the United States, except for certain products exempted due to drug shortages. The restrictions will continue until the facility meets the FDA’s CGMP compliance requirements.
The company added that it remains committed to working closely with the FDA and addressing all observations to bring the facility into full compliance.
Sun Pharmaceutical Industries is the largest pharmaceutical company in India and is a leading generic company in the US as well as Global Emerging Markets.
The company’s consolidated net profit tumbled 19.64% to Rs 2,278.63 crore despite of 10.07% increase in revenue from operations to Rs 13,786.07 crore in Q1 FY26 over Q1 FY25. The drop in profit was primarily due to a one-time exceptional charge of Rs 818 crore during the quarter.
Shares of Sun Pharmaceutical Industries shed 0.33% to Rs 1,589.80 on the BSE.